Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002723 · ClinicalTrials.gov registry record · Phase 3
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
- 20
- Study locations
NCT00002723: Completed Phase 3 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT00002723 is a Phase 3 study of Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 390 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002723, a Phase 3 study of Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.
Conditions Studied
Interventions
- DRUG Suramin
- DRUG suramin
Study Locations (20)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- CCOP - Carle Cancer Center - Urbana
Minnesota
- CCOP - Duluth - Duluth
- Veterans Affairs Medical Center - Minneapolis - Minneapolis
- CCOP - Metro-Minnesota - Saint Louis Park
Michigan
- CCOP - Ann Arbor Regional - Ann Arbor
- CCOP - Kalamazoo - Kalamazoo
New Jersey
- Veterans Affairs Medical Center - East Orange - East Orange
- CCOP - Northern New Jersey - Hackensack
Ohio
- Ireland Cancer Center - Cleveland
- CCOP - Toledo Community Hospital Oncology Program - Toledo
Pennsylvania
- CCOP - Geisinger Clinic and Medical Center - Danville
- CCOP - MainLine Health - Wynnewood
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 1996-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002723
The ClinicalTrials.gov registry entry for NCT00002723 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Suramin is the first listed.
NCT00002723 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Illinois, Minnesota, Michigan.
Frequently Asked Questions
What is clinical trial NCT00002723 about?
NCT00002723 is a clinical study titled "Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer". Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is ...
What is the current status of trial NCT00002723?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 1996-01. Estimated completion is 2008-03.
What conditions does trial NCT00002723 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00002723?
The interventions under investigation include: Suramin (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002723?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002723 being conducted?
This trial has 20 study locations across Illinois, Iowa, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.